Annovis bio inc ANVS.US 總覽分析
ANVS 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分低，若以價值投資為目標且有長期投資部位，需要嚴格執行自己的出場計畫來減持部位
ANVS 近期報酬表現
1.31%
Annovis bio inc
4.57%
同產業平均
3.26%
S&P500
與 ANVS 同產業的標的表現
- ACTU Actuate therapeutics inc價值 -趨勢 3 分波段 5 分籌碼 3 分股利 1 分查看更多
ANVS 公司資訊
Annovis Bio, Inc. is a late-stage clinical drug platform company addressing neurodegeneration such as Alzheimer's disease (AD), and Parkinson's disease (PD). The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.